Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Status:
Not yet recruiting
Trial end date:
2031-11-30
Target enrollment:
Participant gender:
Summary
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes
compared to the current standard treatment available, in patients with relapsed or refractory
follicular lymphoma. This will be done by comparing patients who have received a new
treatment against patients who receive standard treatment based on their response to the
treatment received.